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Abstract: Small, dense low density lipoprotein (sdLDL) represents an emerging 
cardiovascular risk factor, since these particles can be associated with cardiovascular 
disease (CVD) independently of established risk factors, including plasma lipids. Obese 
subjects frequently have atherogenic dyslipidaemia, including elevated sdLDL levels, in 
addition to elevated triglycerides (TG), very low density lipoprotein (VLDL) and 
apolipoprotein-B, as well as decreased high density lipoprotein cholesterol (HDL-C) 
levels. Obesity-related co-morbidities, such as metabolic syndrome (MetS) are also 
characterized by dyslipidaemia. Therefore, agents that favourably modulate LDL 
subclasses may be of clinical value in these subjects. Statins are the lipid-lowering drug of 
choice. Also, anti-obesity and lipid lowering drugs other than statins could be useful in 
these patients. However, the effects of anti-obesity drugs on CVD risk factors remain 
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unclear. We review the clinical significance of sdLDL in being overweight and obesity, as 
well as the efficacy of anti-obesity drugs on LDL subfractions in these individuals; a short 
comment on HDL subclasses is also included. Our literature search was based on PubMed 
and Scopus listings. Further research is required to fully explore both the significance of 
sdLDL and the efficacy of anti-obesity drugs on LDL subfractions in being overweight, 
obesity and MetS. Improving the lipoprotein profile in these patients may represent an 
efficient approach for reducing cardiovascular risk. 
Keywords: lipoproteins; small dense low density lipoprotein; obesity; metabolic 
syndrome; obesity treatment; anti-obesity drugs; lipid-lowering drugs 
 
1. Introduction  
A sedentary lifestyle and high energy diet increases the prevalence of being overweight, obesity, 
metabolic disorders (e.g., metabolic syndrome, MetS) and type 2 diabetes mellitus (T2DM) [1]. 
Obesity and obesity-related co-morbidities, such as MetS and T2DM, are a major health problem 
worldwide [2]. Each of these disorders, in addition to established vascular risk factors  
(e.g., dyslipidaemia, smoking and hypertension) increases the risk of cardiovascular disease (CVD). 
Therefore, the American Diabetes Association and the American College of Cardiology Foundation 
recommend a multifactorial risk reduction strategy targeting each risk factor and underlining both 
lifestyle and pharmacological treatment [3]. 
A commonly observed lipid abnormality in obese individuals (especially those with excess central 
adipose tissue), is an increased presence of small dense low-density lipoprotein (sdLDL) [4–6]. This 
predominance of sdLDL particles is associated with raised triglycerides (TG) and decreased high 
density lipoprotein cholesterol (HDL-C) levels, forming the so-called ―atherogenic lipid triad‖ [7,8]. 
Adipose tissue also produces a diversity of adipokines that play a role in the pathogenesis of 
inflammation, dyslipidaemia and hypertension [9] that increase the rate of CVD morbidity and 
mortality linked to obesity, T2DM and the MetS [10]. Excessive visceral adiposity enhances the 
availability of free fatty acids (FFA) that lead to TG accumulation in muscle and liver (fatty liver) and 
increase circulating TG levels, due to the enhanced hepatic production of very low density lipoprotein 
(VLDL) cholesterol [11–13]. Furthermore, the raised flux of FFA and TG to muscle and other tissues 
induces insulin resistance (IR) [14,15]. 
LDL varies in size, density and metabolic characteristics and comprises at least four distinct 
subclasses (large LDL-I, medium LDL-II, small LDL-III and very small LDL-IV (Table 1)), with 
sdLDL being associated with increased CVD risk [16]. Although the association between IR and 
increased LDL-C levels is not typical, elevated sdLDL levels with lower large LDL concentrations are 
associated with reduced insulin sensitivity and increased adiposity [17–19]. Generally, two phenotypes 
have been described: pattern A, with a higher proportion of larger, more buoyant or medium-sized 
LDL, and pattern B, with a predominance of sdLDL [16]. The difference in size and density among 
LDL subclasses is due to variations in surface lipid content and conformational changes in apoB-100, 
including increased exposure on the particle surface [20]. 
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Table 1. Physicochemical properties of low-density lipoprotein (LDL) subclasses  
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Sf: Svedberg flotation. 
Search Strategy: We searched PubMed and Scopus listings for relevant publications using 
combinations of the following keywords: ―lipids‖, ―lipoproteins‖, ―small dense low density 
lipoprotein‖, ―high density lipoprotein‖, ―overweight‖, ―obesity‖, ―obesity treatment‖, ―anti-obesity 
drugs‖, ―lipid-lowering drugs‖ and ―new anti-obesity drugs‖. 
2. The Clinical Relevance of sdLDL 
sdLDL tend to coexist with elevated TG and low HDL-C levels and together comprise the 
―atherogenic dyslipidaemia‖ pattern, which appears to be heritable, but also several non-genetic 
factors, such as abdominal adiposity, influence the expression of this phenotype [16]. However, it is 
still debated whether LDL particle size is an independent CVD risk factor after adjustment for TG and 
HDL-C levels [21]. 
In relation to large buoyant LDL, sdLDL particles are taken up more easily by arterial tissue, show 
lower affinity for the LDL receptor, have a longer half-life in plasma and greater oxidative and 
glycation susceptibility, suggesting a link between sdLDL particles and atherogenesis [22,23]. It has 
been shown that subjects with high levels of sdLDL particles have an approximately three- to seven-fold 
increase in the risk of developing coronary heart disease (CHD), independently of LDL-C 
concentration [24–26]. Some studies found that subjects at high CVD risk, such as those with 
peripheral arterial disease or abdominal aortic aneurysm, may also have higher levels of these 
particles [27,28]. Further, a significant relationship between LDL size and the occurrence of carotid 
atherosclerosis was reported [29–31]. In different metabolic diseases (e.g., polycystic ovary syndrome, 
growth hormone (GH) deficiency) [32–34] and in women with gestational diabetes [35], increased 
levels of sdLDL were also found.  
sdLDL also represents a marker for diagnosis and severity of the MetS [36,37]. In this context,  
we confirmed that sdLDLs are increased in the MetS and showed an independent predictive role for 
future cardiovascular and cerebrovascular events [38]. Additionally, it has been suggested that the  
sdLDL-C/LDL-C ratio correlates with various parameters associated with MetS rather than the LDL-C 
or sdLDL-C levels, thus possibly representing a more useful clinical indicator [39]. Furthermore, an 
increased sdLDL-C/LDL-C ratio was an independent factor determining decreased adiponectin levels 
in MetS patients [39], but the mechanisms involved need to be elucidated. 
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3. Overweight, Obesity and sdLDL 
Visceral obesity and IR have been recognized as the main causes of raised levels of sdLDL, because 
these factors contribute to postprandial hypertriglyceridemia; an essential mechanism is increased FFA 
release from adipocytes, which stimulates hepatic TG output [11,13]. Additionally, if fatty liver is 
present, upregulated de novo synthesis of FFA may increase hepatic TG production and affect the 
hepatic metabolism of TG and/or LDL-C, resulting in increased sdLDL levels and rapid atherogenesis 
in patients with MetS or T2DM [40]. In such metabolic conditions, fatty liver may enhance 
atherogenesis by raising the levels of sdLDL particles [41,42]. Hosoyamada et al. suggest that fatty 
liver may affect LDL particle size independently of both visceral obesity and IR [40]. Thus, treatment 
of fatty liver might decrease atherogenesis in MetS or T2DM by reducing sdLDL-C levels.  
Currently, there is renewed interest in the usefulness of measuring non-fasting TGs, as a more 
powerful and independent predictor of CVD risk than fasting levels [43]. In this context, an expert 
panel provided a consensus statement on the classification of non-fasting TGs concentration and other 
related clinical recommendations [44]. Standard reference values for post-prandial TG levels were 
suggested based on a recent meta-analysis [45]. 
Data from the Mima study [46] indicate that a polymorphism of the beta(3)-adrenergic receptor 
gene (the genetic marker for obesity-related traits) is correlated with the area percentage of sdLDL  
(p < 0.05), independently of age, gender, body mass index (BMI), smoking and IR index, suggesting a 
genetic predisposition to increased sdLDL in the presence of this polymorphism. 
Weight loss in obese, non-diabetic women resulted in a significant reduction of the levels of 
lipoprotein-associated phospholipase A2 (Lp-PLA2) (p < 0.01), a phospholipase primarily associated 
with LDL, especially with sdLDL, while neither the cholesterol levels of sdLDL particles nor the 
percentage of the sdLDL-cholesterol of the total LDL-C were changed [47,48]. This change in  
Lp-PLA2 activity correlated with the changes in VLDL levels (p < 0.05) and could be a potentially 
new predictor for atherosclerotic disease. Lp-PLA2 is also a marker of sdLDL in human plasma [49]. 
Alternate day modified fasting (ADMF) is a dietary restriction that could help overweight and 
obese individuals to lose weight and lower CHD risk [50]. After eight weeks of ADMF, peak and 
integrated LDL particle size, as well as the proportion of large LDL particles increased, whereas the 
proportion of small and medium particles decreased (for all comparisons, p < 0.05). Cholesterol level 
in large particles did not alter, whereas this parameter was reduced within small- and medium-sized 
LDL particles (p < 0.05). Furthermore, LDL particle size was associated with reduced body weight  
(p = 0.04) and smaller waist circumference (p = 0.03). On the other hand, no association was observed 
between LDL particle size and plasma TGs (p = 0.11) or HDL-C concentrations (p = 0.65) [51], 
although reductions in plasma LDL and TGs concentrations were observed. However, given that the 
effect of weight loss on LDL particle size was not evaluated separately from the effect of fasting, it 
remains unclear whether these cardioprotective effects were due to reduced body weight or the 
prolonged fasting period. Future studies are needed to elucidate these effects on changes in  
lipoprotein subfractions. 
The effects of glucose- or fructose-sweetened beverages have been investigated in overweight and 
obese subjects, and differential effects were shown on adipose distribution [52]. Both total abdominal 
fat and visceral adipose tissue (VAT) volume were increased in individuals consuming fructose,  
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while only subcutaneous adipose tissue volume was significantly increased in those consuming 
glucose. Fructose raised sdLDL, oxidized LDL (oxLDL) and postprandial remnant-like particle 
lipoprotein-cholesterol (RLP-C) and RLP-TG, whereas glucose consumption did not [44]. 
Furthermore, sdLDL was mostly affected by pre-existing MetS risk factors (MSRF), and the increase 
in sdLDL levels during fructose consumption was more than two-fold greater in subjects with three 
MSRF than in those with zero to two MSRF [52]. Finally, consumption of fructose at 25% of energy 
requirements with an ad libitum diet decreased glucose tolerance and insulin sensitivity (greater in 
women than in men) compared with glucose consumption. 
A high prevalence of sdLDL in obese children, as well as a relationship between peak LDL 
diameter and abdominal fat accumulation, and the level of both HDL-C and TG was reported [53]. 
When changes in LDL subfractions during a weight loss intervention for overweight and obese 
children were investigated, a reduction in cholesterol concentration of LDL III particles  
(54.1 vs. 40.4 mg/dL; p < 0.01), and shift in mean LDL-C peak particle density (1.041 vs. 1.035 g/mL) 
was found [54]. These alterations were also positively and significantly correlated to changes in VLDL 
metabolism. In contrast, in a later study [55], statistical difference was reported in the LDL particle 
size between 26 obese and 27 healthy children (p = 0.575); the size of LDL particles was not 
correlated with BMI, homeostasis model assessment (HOMA)-IR or serum lipids, although obese 
children had increased TGs and low HDL levels. Based on these results, the authors suggested that 
LDL particle size measurement is not necessary in childhood obesity as a routine procedure. A 
potentially explanation for these different results might be genetic factors and age in different 
populations [55]. Postprandial pro-atherogenic factors in obese boys were significantly improved after 
two different meals: moderate fat (MF: 61% carbohydrate, 27% fat) vs. high fat (HF: 37% carbohydrate, 
52% fat). OxLDL concentration was raised after the HF, but not after the MF meal (9.3(2.2)% vs. 
1.8(2.2)% from baseline, p < 0.02) and the densest LDL particles were associated positively (p < 0.05) 
with oxLDL levels. HDL-C concentration was lower (p < 0.05) at 300 min after HF vs. MF meal [56]. 
These results indicate that an evaluation of postprandial lipids may be relevant in children, as 
suggested earlier [57].  
Reduced GH secretion in obesity could be associated with atherogenic dyslipidaemia, including 
raised sdLDL particles, given that reduced peak-stimulated GH in obesity was independently associated 
with a more atherogenic lipoprotein profile defined in terms of particle size (p < 0.0001) [58,59].  
In this study, obese patients with reduced GH secretion had a smaller mean LDL and HDL particle size 
in comparison with normal weight or obese subjects with sufficient GH (p < 0.0001). 
In another study where the ethnic difference in lipid levels and LDL particle size and subclasses 
were investigated, obese black women had significantly more sdLDL (subclass IV) compared with 
obese white women [60]. 
In summary, the entities of MetS and obesity, with a clinical clustering of CV risk factors and 
underlying IR, are also associated with phenotypical changes in lipoprotein patterns that increase the 
atherosclerotic potential of circulating lipids and their interaction with the vessel wall and 
endothelium. LDL subfraction is positively correlated with higher waist circumference, higher serum 
TG, as well as older age and more statin usage in hypertensive patients. Thus, LDL size could 
represent a risk factor associated with endothelial dysfunction in hypertension [61]. Further, in vitro 
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studies, using cultured endothelial cells, have shown that LDL subfractions from hypercholesterolemic 
patients may deregulate endothelial function [62]. 
The main outcomes of discussed studies in this review are listed in Table 2. 
Table 2. Outcomes of the observed studies that have analysed small dense low density 
lipoprotein cholesterol (sdLDL) in overweight and obese subjects. 
Study Patients sdLDL and measurement Outcome of the study 
Satoh N  
et al. [39] 
214 subjects  
(97 men and  
117 women) 
↑ 
in subjects with MetS  
A dual detection HPLC and 
a Lipoprint LDL system 
The ratio of sd-LDL-C/LDL-C is a 
more useful clinical indicator than 
sdLDL 
Tsuzaki K  
et al. [46] 






Genetic predisposition to increased 
sdLDL in subjects with polymorphism 
of the beta(3)-adrenergic receptor gene 
Tzotzas T  
et al. [47] 
28 obese, non-diabetic 
women 
↔ 
3% polyacrylamide gel-tube 
electrophoresis; Lipoprint 
LDL System (Quantimetrix, 
Redondo Beach, CA) 
A low-calorie diet reduces the levels of 
Lp-PLA2; the levels of sdLDL 
particles were not changed 
Varady KA  
et al. [51] 
60 obese subjects 
↓ 
Non-denaturing 2%–16% 
polyacrylamide gradient  
gel electrophoresis 
ADMF is an efficient strategy for 
decreasing of sdLDL level and 
increasing LDL particle size 
Stanhope KL  
et al. [52] 
32 overweight and 
obese subjects 
↑ 
(with fructose) Precipitation 
Dietary fructose promotes 
dyslipidaemia 
Miyashita M  
et al. [53] 
30 obese children 
↑ 
Gel electrophoresis 
High prevalence of sdLDL in obese 
children; a relationship of peak LDL 
diameter with abdominal fat 
accumulation, HDL-C and TG levels 
King RF  
et al. [54] 




Reduction in LDL-C, LDL-C III and 
LDL-C peak particle size 
Tascilar ME  
et al. [55] 
26 obese children  
(13 girls, 13 boys) 
↔ 
Polyacrylamide gradient  
gel electrophoresis 
Measurement of LDL particle size is 
not necessary in childhood obesity 
Maffeis C  
et al. [56] 
10 obese boys 
↑ 
After the HF meal  
(abstract; no data  
for measuring) 
A change of ≈25% of energy load from 
fat to carbohydrate in a meal improves 
postprandial pro-atherogenic factors in 
obese boys 
Makimura H  
et al. [58] 
102 normal weight 
and obese men  
and women  
↑ 
GH↓ 
GH stimulation testing and 
NMR spectroscopy 
An independently association between 
reduced peak-stimulated GH and an 
atherogenic lipoprotein profile in 
obesity 
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Table 2. Cont. 
Goedecke JH  
et al. [60] 
15 normal-weight black;  
15 normal-weight white; 
13 obese black;  
13 obese white South 
African women 
↑ 
Non-denaturing 2 to 16% 
polyacrylamide gradient gel 
electrophoresis 
Obese black women had 
significantly more sdLDL 
compared to obese white women 
Filippatos TD  
et al. [63] 
89 overweight and obese 
patients 
↓ 
3% polyacrylamide  
gel-tube electrophoresis; 
Lipoprint LDL System 
(Quantimetrix, 
Redondo Beach, CA) 
Orlistat + fenofibrate led to a 
greater reduction in sdLDL-C 
levels and favourable effects on  
Lp-PLA2 
Nakou ES  
et al. [64] 




3% polyacrylamide gel-tube 
electrophoresis; Lipoprint 
LDL System (Quantimetrix, 
Redondo Beach, CA) 
The combination orlistat and 
ezetimibe have a more favourable 
effect on LDL-C and sdLDL-C 
levels than either drug alone 
LDL-C—low density lipoprotein cholesterol; sdLDL—small dense LDL; HDL-C—high density lipoprotein 
cholesterol; TG—triglycerides; Lp-PLA2—lipoprotein-associated phospholipase A2; GH—growth hormone; 
ADMF—alternate day modified fasting, MetS—metabolic syndrome; HF—high fat; NMR—nuclear 
magnetic resonance; ↑: increased; ↓: decreased; ↔: no effect. 
4. Treatment Options 
Given that obese individuals with mixed dyslipidaemia have raised sdLDL-C levels, agents that 
have a potential beneficial effect on this LDL phenotype may be useful [65]. In visceral obesity, drugs, 
such as statins, fibrates and insulin sensitizers [66], are often required to correct any associated 
dyslipidaemia [67]; cannabinoid receptor type 1 blockers (such as rimonabant) are not currently on the 
market [52]. Furthermore, statins and other hypolipidemic agents (e.g., ezetimibe and fibrates), as well 
as weight-reducing agents were reported to favourably affect LDL subfractions [63,64]. Briefly, 
ezetimibe decreased the large and medium LDL particles and, to a lesser extent, the sdLDL particles, 
while it had no influence on LDL size; however, its sdLDL lowering capacity may be enhanced in 
individuals with elevated TG levels [65,68]. It seems that fenofibrate is equally or even more effective 
than statins in reducing sdLDL levels and increasing LDL size [69]. Fibrates and niacin reduced 
sdLDL levels and shifted LDL size towards large, buoyant LDL particles [70]. 
It was shown that a normalization of adiposity could lead to conversion from pattern B to pattern A 
LDL phenotype [71]; weight loss through energy restriction also increased LDL particle size and, thus, 
reduced CHD risk in obese subjects [72]. Several anti-obesity drugs were withdrawn from use over the 
past few years, due to adverse events, and currently, orlistat is available for long-term obesity 
management [66]. Orlistat significantly reduced both LDL-C and sdLDL-C levels (−19% and −45%, 
respectively, all p < 0.01); however, the decrease in sdLDL-C levels (−76%; p < 0.01 vs. baseline) and 
the increase in LDL particle diameter (+1.4%; p < 0.01 vs. baseline) were greater with the combination 
of ezetimibe and orlistat compared with either monotherapy (p < 0.05) [64]. These authors explained 
this greater fall in sdLDL-C levels by the greater decrease in TG in the combination group compared 
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with monotherapy. In addition, orlistat, in both cases, alone or in combination with ezetimibe, 
improved anthropometric and metabolic variables (BMI, HOMA, serum uric acid, transaminase 
activities and plasma Lp-PLA2 [64]). In an earlier study, multiple regression analysis showed that the 
orlistat-induced reduction in sdLDL-C levels was significantly and independently correlated with the 
reduction in TG and HOMA [63]; orlistat raised sdLDL-C levels by 35% (p < 0.05 vs. baseline) and 
LDL particle diameter by 0.7% (non-significantly, p > 0.05). Furthermore, the combination treatment 
(orlistat + fenofibrate) was associated with decreases in VLDL-C (−36%; p < 0.01 vs. baseline) and 
sdLDL-C levels (−77%; p < 0.001 vs. baseline), as well as the proportion of the sdLDL-C of the total 
LDL-C (−68%; p < 0.01 vs. baseline) [63]. Orlistat + fenofibrate led to a greater reduction in sdLDL-C 
levels (p <0.05), together with a greater increase in LDL particle diameter (p < 0.05) compared with 
the orlistat group. Lp-PLA2 activity was also significantly decreased [63]. In addition, it was 
suggested that orlistat, alone or in combination with fenofibrate, may decrease LDL concentrations in 
obese MetS patients, confirming the findings that obese T2DM subjects with MetS orlistat + diet 
improved several CVD risk factors (fasting glucose, glycosylated haemoglobin (HbA1c), total 
cholesterol (TC) and LDL-C levels, systolic blood pressure (SBP), waist circumference and HOMA) 
compared with diet and exercise alone [73].  
Bariatric surgery is an effective treatment option in young obese patients with BMI > 40 kg/m
2
 or 
BMI > 35 kg/m
2
 in the presence of significant comorbidities [74,75]. A gender-dependent relationship 
between excess weight loss (EWL) and lipid subfractions (reduced TC, LDL-C, TG and HOMA-IR;  
p < 0.0005 for all) after laparoscopic Roux-en-Y gastric bypass (LRYGB) has been reported [76]. 
Furthermore, a reduction of sdLDL with a rise in LDL relative flotation was observed after 
laparoscopic gastric banding (LAGB) (0.34 ± 0.04 vs. 0.38 ± 0.03; p < 0.001), but neither weight 
reduction nor changes in phospholipid fatty acid composition were found, despite a reduction in TG 
levels [77]. In general, LRYGB seems to be more effective, safer and has lower mortality rates 
compared with LAGB [78]. 
Although rimonabant has been withdrawn from the market, monotherapy with this drug led to a 
decreased sdLDL proportion [79,80], whereas in combination with ezetimibe or fenofibrate,  
a non-significant reduction in sdLDL was observed [65]. The effect of sibutramine, which has also 
been withdrawn from the market, on the sdLDL profile has not been described. Recently, a  
meta-analysis reported that orlistat and rimonabant could lead to an improvement in CVD risk factors 
(reduced SBP, diastolic BP, TC, LDL, fasting glucose, as well as body weight), whereas sibutramine 
might increase CVD risk factors (i.e., hypertension); future studies should fully elucidate the effects of 
any similar drugs on cardiovascular risk factors, if they are marketed [81]. 
5. Effects of New Anti-Obesity Drugs on Lipids  
In the field of anti-obesity drugs, the U.S. Food and Drugs Administration (FDA) has recently 
(June–July 2012) approved two new agents, namely lorcaserin (Belviq; a selective 5-hydroxytryptamine 
receptor 2c agonist) [82] and qsymia (formerly named qnexa, a combination of phentermine with 
controlled release topiramate) [83]. Of note, lorcaserin is contraindicated in combination with drugs 
for migraine and depression, as well as agents that can activate serotonin receptors or increase 
serotonin [82]. Patients with valve abnormalities should be carefully monitored, as serotonin receptors 
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may induce valvular heart disease [84]. With regard to qsymia, heart rate should be monitored 
regularly during treatment, whereas patients with hyperthyroidism, glaucoma, recent (within the last 
six months) or unstable heart disease and stroke should not receive it [83]. Both drugs should be 
discontinued if <5% of initial body weight is lost within three months of treatment. 
Contrave (naltrexone sustained-release (SR) combined with bupropion SR) was rejected by the 
FDA in 2011, due to concerns on CVD risk; however, the FDA agreed to consider the results of a 
currently running cardiovascular outcomes [85]. These anti-obesity drugs were shown not only to 
reduce weight, but also to beneficially affect the cardiometabolic profile of obese patients (e.g., waist 
circumference, lipids, fasting glucose and insulin sensitivity) [86–88]. With regard to lipids, these 
drugs were reported to significantly reduce TC, LDL and TG and increase HDL [86,88–90]. However, 
these data are scarce and, even more, no data exist regarding sdLDL. Future larger studies are needed 
to establish the effect of these anti-obesity drugs on lipids. 
6. Effects of Lipid-Lowering and Anti-Obesity Drugs on HDL Subfractions 
HDL-C also circulates in several subclasses with different properties, composition, metabolism and 
pathophysiological significance [91,92]. The HDL subfraction distribution may potentially affect the 
multiple actions of HDL with clinical consequences [93,94], but the role of each individual HDL 
subfraction on CVD risk remains inconclusive [95,96]. 
MetS has been linked to increased small HDL-3 particles and reduced large HDL-2 levels [97]. 
Patients with acute ischemic stroke were reported to have smaller HDL size with less HDL 2b and 
more HDL 3a, 3b and 3c subclasses [98]. 
Interestingly, atorvastatin was shown to increase HDL particle size in hyperlipidemic patients [99]. 
Similarly, rosuvastatin alone or in combination with ω-3 fatty acids raised larger HDL subfractions, 
whereas rosuvastatin with fenofibrate increased small HDL levels [100]. 
Gemfibrozil was found to increase small HDL subclasses in the Veterans Affairs High-Density 
Lipoprotein Intervention Trial (VA-HIT) [101]. In contrast, when combined with niacin, gemfibrozil 
raised large HDL-2 levels [102]. 
Niacin treatment was associated with increases in large HDL particles in both type 2 diabetics [103] 
and hyperlipidemic patients [102]. Interestingly, the beneficial effects on HDL particles (i.e., increase 
in large HDL and reduction in small HDL) were numerically greater following niacin plus simvastatin 
combination therapy compared with atorvastatin monotherapy in a post-hoc analysis of 137 hyperlipidemic 
patients of the SUPREME study [104]. In another study, niacin monotherapy, as well as its 
combination with simvastatin raised both HDL-3 and HDL-2 levels, the latter in a relatively greater 
degree, in dyslipidemic individuals [105].  
Pioglitazone and metformin were shown to beneficially affect both LDL and HDL subclasses in 
type 2 diabetic patients [106,107]. In contrast, rosiglitazone was found to increase smaller HDL and 
reduce larger HDL particles in patients with T2DM [108], as was troglitazone [109]. Of note, both 
rosiglitazone and troglitazone were withdrawn from the market, due to severe adverse effects 
(cardiovascular and hepatic disorders, respectively). 
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Cilostazol, a selective inhibitor of phosphodiesterase 3A used in patients with intermittent 
claudication to improve their walking distance, was also shown to beneficially affect HDL 
subclasses [110]. This may be relevant if obese patients have peripheral artery disease.  
In obese hyperlipidemic patients, orlistat and ezetimibe, alone or in combination, although not 
affecting HDL quantity, led to significant changes in HDL quality [111]. In detail, orlistat raised  
HDL-2 and decreased HDL-3 subclasses, whereas ezetimibe and their combination reduced HDL-3 
subfraction. Similarly, in another study with obese MetS patients, orlistat increased large HDL and 
decreased small HDL subclasses, whereas fenofibrate raised small HDL particles [112]. Ezetimibe was 
also reported to reduce small HDL subfractions in patients with primary dyslipidaemia [113]. 
With regard to the new anti-obesity drugs (i.e., lorcaserin, qsymia and contrave), no data exist on 
their impact on HDL subclasses; future studies are required to evaluate any possible effect. 
Small HDL3c particles in MetS subjects failed to protect endothelial cells from oxLDL-induced 
apoptosis, and a negative correlation between HDL3c-mediated protection from apoptosis and waist 
circumference, plasma TG, TC/HDL-C ratio and oxLDL were found [114]. This deficiency in  
anti-apoptotic activity of small HDL was associated with altered apolipoprotein and lipid composition. 
7. Lifestyle as the First-Line Therapeutic Option 
Changes in the HDL profile were reported in overweight diabetic men and women following weight 
reduction [115]. Weight loss has been suggested as an effective method in reversing the decrease in 
HDL levels in obesity, and weight loss achieved through exercise is more effective than weight loss 
achieved by diet [116]. In a study with 46 obese subjects [117], only the combination of alternate day 
fasting plus exercise resulted in decreased LDL-C (p < 0.05) and increased HDL-C (p < 0.05) with a 
decreased proportion of small HDL particles (p < 0.01) compared with each intervention alone. 
Several recent meta-analyses [118–120] have also reported beneficial effects of exercise on lipids and 
lipoproteins in patients with MetS, in accordance with the results of many studies that have reported 
that exercise could have an important role in increasing HDL-C level [117,121,122]. Interestingly, 
when associations of all-cause mortality, adiposity and fitness were examined in older adults, fitness 
was inversely associated with mortality, and results were changed a little by adjustments for adiposity 
or fat distribution [123]. Thus, the authors have found that both fitness and BMI are independent 
predictors of all-cause mortality in adults 60 years old or older, emphasizing that further studies are 
needed to confirm if total adiposity per se may be the factor that increases mortality risk. The same 
authors have shown that lower levels of fitness are also associated with a higher risk of all-cause and 
CVD mortality in younger and middle-aged men [124,125]. 
In a six-month randomized study [126] performed in 78 severely obese subjects (86% of them had 
either diabetes or MetS), the authors found a favourable effect of a low carbohydrate diet on 
lipoprotein subfractions compared with a conventional diet, while both diets similarly decreased LDL 
particles and increased large HDL. In addition, both diets significantly decreased postprandial lipemia 
and led to similar (but non-significant) alterations in the total cholesterol/HDL-C ratio, fasting 
triacylglycerols, oxLDL and LDL subclasses distribution [127]. However, a very low carbohydrate 
diet prevents a decrease in HDL-C, although it did not lower LDL-C compared with a low-fat weight 
loss diet [127]. Similar results were also achieved when both diets were consumed for weight 
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maintenance rather than weight loss, thereby reducing the effect of change in body weight on 
lipids [128]. In a study that compared the effects of pioglitazone vs. diet/exercise on body fat, glucose 
and lipid metabolism in obese, insulin-resistant individuals [129], only diet/exercise reduced total 
cholesterol, TG and LDL-C concentrations, whereas both treatment increased large LDL and 
decreased sdLDL particles. Furthermore, a Mediterranean-style diet rich in fruits and vegetables and 
with high polyunsaturated fats reduced cardiovascular events and decreased LDL-C with a 
concomitant increase in HDL-C [130]. 
Increased physical activity may improve sdLDL in hyperlipidemic subjects [131]. In general, 
lifestyle modification is the first-line therapy [132], with smoking cessation, exercise,  
mild-to-moderate alcohol consumption and weight loss increasing HDL-C in patients with levels  
<40 mg/dL [133]. In summary, first-line therapy in obese patients should be a healthy diet and 
physical activity. Lipid-lowering therapies should be prescribed only after or together with lifestyle 
modifications, unless the risk of a vascular event is so high that the prescribing clinician elects not to 
delay effective pharmacological intervention. If after statins therapy, HDL-C remains low, then niacin 
should be prescribed. 
It is known that increased LDL-C (including decreased HDL-C) is one of several factors that are 
linked with high cardiovascular risk. However, the exact mechanisms by which LDL particle size may 
act as an independent CVD risk factor remains unclear. Currently, there is no strong clinical evidence 
to show that targeting lipoprotein subfractions is useful or recommended. Further large studies are 
needed to elucidate the clinical implications of lipoprotein subfractions, as well as to establish the 
effect of the here mentioned anti-obesity drugs on lipoproteins. 
8. Conclusions 
In overweight and obese hypercholesterolemic subjects, statins are the first treatment choice. 
Orlistat and ezetimibe coadministration had a more favourable effect on LDL-C and sdLDL-C levels 
than either drug alone [64]. This combination also exhibited favourable effects on Lp-PLA2 activity 
and LDL phenotype in overweight and obese patients with MetS, but positive effects on the LDL 
distribution profile should be replicated in larger studies. ADMF may increase LDL particle size, thus 
decreasing the sdLDL proportion, and ADMF could be a suitable alternative to traditional energy 
restriction for lowering CVD risk in obese individuals. 
Anti-obesity medications, either as monotherapy or in combination with other drugs, presented 
encouraging results in terms of weight loss, safety and improvement of cardiometabolic risk factors. 
Combinations of drugs targeting different pathways in low doses may have better results than 
strategies that modify one pathway alone; this might represent the future strategy in obesity treatment.  
Improving the quantity and the quality of lipoproteins in obesity and the MetS may represent an 
effective approach to reduce cardiovascular risk. 
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